What is the efficacy and tolerability of pindolol plus selective serotonin reuptake inhibitors (SSRIs) in people with depression?

**METHODS**

**Design:** Systematic review with meta-analysis.


**Study selection and analysis:** Eligible studies were randomised controlled trials (RCTs) comparing pindolol plus SSRIs with placebo plus SSRIs in people with depression. RCTs examining early response (between 10 days and 2 weeks) and late response (3–6 weeks) were included. Studies involving non-SSRI antidepressants and crossover RCTs were excluded. Sensitivity and heterogeneity analyses were conducted.

**Outcomes:** Depressive symptoms: efficacy assessed by the number of participants responding to treatment (defined as a decrease of ≥50%; or similar criterion, on the Hamilton Depression Rating Scale (HDRS) or Montgomery-Asberg Depression Rating Scale (MADRS)). Tolerability: proportion of the total study population not completing the study. Safety: proportion of total participants experiencing side effects.

**MAIN RESULTS**

Nine RCTs met inclusion criteria (594 participants).

**Early response:** five RCTs met inclusion criteria. Pindolol plus SSRIs significantly improved depressive symptoms compared with placebo plus SSRIs, for the first two weeks of treatment (OR 2.8, 95% CI 1.4 to 5.7; NNT = 6, 95% CI 4 to 20).

**Late response:** seven RCTs met inclusion criteria. There were no significant differences between groups after 3–6 weeks (OR 1.4, 95% CI 0.8 to 2.7). However, the late response studies were heterogeneous.

**Tolerability and safety:** there were no significant differences in tolerability or adverse events between groups (pindolol plus SSRIs v placebo plus SSRIs; OR for tolerability, 1.3, 95% CI 0.8 to 2.3; OR for adverse events, 1.3, 95% CI 0.7 to 2.1).

**CONCLUSIONS**

During the first two weeks of treatment, the addition of pindolol to an SSRI appears to increase response; however there was no evidence of improved efficacy beyond this period.

---

For correspondence: Javier Ballesteros, Department of Neuroscience, Medical Psychology and Psychiatry, University of the Basque Country, Barria Sarriena, Leioa, Spain; onpbaroj@lg.ehu.es

Sources of funding: none specified.

---

Commentary

All the current arguments about the mechanism and efficacy of antidepressants, virtually everyone can agree that there is a delay—the antidepressant “latency”—before the specific anti-depressant effect is clear. It is common for the antidepressant effect to be delayed. The formulation of a rapidly acting antidepressant would be a major landmark. Manufacturers’ claims of rapid onset for their particular drug should be regarded with caution, as clinical trials are not usually designed with time of onset in mind.

The problem is complicated because we do not know why latency occurs. Selective serotonin reuptake inhibitors (SSRIs) selectively inhibit serotonin reuptake by the 5-HT1A antagonist pindolol could reduce this latency—and so it proved in open label studies. The key was of course to test the effect in randomised controlled studies.

Results have been mixed. Roughly speaking, in European hands (including our own), the addition of pindolol from the outset of antidepressant (not only with SSRIs) treatment does indeed seem to accelerate the antidepressant response in many patients, especially if they have not been treated for depression before (the severity of the depression seems to be less important). However, some US studies have been less successful, as have studies looking at treatment resistance.

So the true place of pindolol augmentation remains debated, with the problem complicated because we do not know why latency occurs. Selective serotonin reuptake inhibitors (SSRIs) selectively inhibit serotonin reuptake by the 5-HT1A antagonist pindolol could reduce this latency—and so it proved in open label studies. The key was of course to test the effect in randomised controlled studies.
Review: combining pindolol with an SSRI improves early outcomes in people with depression

Evid Based Mental Health 2004 7: 107
doi: 10.1136/ebmh.7.4.107

Updated information and services can be found at:
http://ebmh.bmj.com/content/7/4/107

These include:

References
This article cites 6 articles, 0 of which you can access for free at:
http://ebmh.bmj.com/content/7/4/107#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Clinical trials (epidemiology) (989)
- Depressive disorder (570)
- Epidemiology (1570)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/